Bone cancer
Drug research and approvals for bone cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 717 studies of bone cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 1 open orphan designations naming it.
- Recruiting worldwide: 717
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Shadow-Mode Evaluation of an AI Assistant for Multidisciplinary Tumor BoardsNCT07939139 · Not reported · Technical University of Munich · starts Nov 9, 2026
- Eggshell-Derived Hydroxyapatite With Platelet-Rich Fibrin for Bone Regeneration After Jaw Cyst RemovalNCT07933185 · Not applicable · Ahmed Nasser Ali Mabkhout · starts Sep 14, 2026
- Airway Ultrasound in Oncologic Maxillofacial PatientsNCT07910149 · Not reported · University Hospital Dubrava · starts Sep 1, 2026
- A Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIsNCT07905183 · Phase 3 · Enliven Therapeutics · starts Dec 31, 2026
- Safety and Tolerability of Metformin and Naproxen for Cancer Prevention in Fanconi AnemiaNCT07901959 · Phase 1 · Rockefeller University · starts Oct 14, 2026
- Using an Artificial Intelligence (AI) Tool for Melanoma DiagnosisNCT07890415 · Phase 3 · Memorial Sloan Kettering Cancer Center · starts Oct 15, 2026
- Medical Payment Case Management for Financial Toxicity in Patients With Primary Bone Tumors: A Randomized Controlled…NCT07888244 · Not applicable · Shanghai 6th People's Hospital · starts Sep 19, 2026
- Sonrotoclax Plus Azacitidine in Patients With MDS-IB2NCT07885397 · Phase 1 / Phase 2 · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · starts Oct 15, 2026
- A Study of Ropeg-Interferon in People With Polycythemia VeraNCT07886801 · Phase 2 · Memorial Sloan Kettering Cancer Center · starts Oct 30, 2026
Phase 3 4
- Zoledronic acidFarnesyl diphosphate synthase inhibitor
- Ibandronic acidFarnesyl diphosphate synthase inhibitor
- Tranexamic acidPlasminogen inhibitor
- DexmedetomidineSpinal cancer · Adrenergic receptor alpha-2 agonist
Phase 2 9
- CarboplatinDNA inhibitor
- DoxorubicinDNA topoisomerase II alpha inhibitor
- IrinotecanDNA topoisomerase I inhibitor
- LomustineDNA inhibitor
- PaclitaxelTubulin inhibitor
- GemcitabineRibonucleoside-diphosphate reductase RR1 inhibitor
- CatequentinibVascular endothelial growth factor receptor 2 inhibitor
- EtoricoxibCyclooxygenase-2 inhibitor
- ElraglusibGlycogen synthase kinase-3 beta inhibitor
Phase 1 or earlier 3
- RegorafenibTyrosine-protein kinase ABL inhibitor
- TeprosulvoseNose cancer
- Indocyanine green acid formDiagnostic agent
How its trials ended
289 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 59 whose ending is known, 32% met their primary endpoint, 3% missed it and 64% stopped early.
- Completed, result not reported10536%
- Ongoing8228%
- Status unknown4315%
- Stopped: other or unclear217%
- Met its primary endpoint197%
- Stopped: enrollment or feasibility114%
- Missed its primary endpoint21%
- Stopped: lack of efficacy21%
- Stopped: sponsor or business decision21%
- Stopped: funding21%
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Jun 15, 2007 | 5(S)-(2'-hydroxy ethoxy)-20(S)-CamptothecinTreatment of osteosarcoma (bone cancer) | Dr. Reddy's Laboratories, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA